Full transparency sets a new standard for quality

Jul 21, 2017

Blueprint Genetics is committed to provide the highest quality genetic testing for our customers. Since quality is something that can be proven, we are proud to transparently share our full set of quality metrics with you. To be able to show the different aspects of quality in genetic testing, we…

Read more

Introducing the updated and improved ophthalmology genetic diagnostic panels

Jun 22, 2017

Blueprint Genetics has been working towards improving the quality and performance of genetic diagnostic testing for patients with inherited eye disorders. All panels are based on our unique OS-Seq technology that enables high-quality analysis of single nucleotide variants (SNVs), insertions and deletions (indels) and copy number variations (CNVs). Our technological innovations…

Read more

Panel update for ophthalmology, gastroenterology, and pulmonology

Jun 01, 2017

We are excited to announce the latest updates to our test menu. We have added some deep intronic and non-coding variants to the tested target regions that have been reported as pathogenic in the literature and are classified as likely pathogenic or pathogenic in ClinVar. These include for example the recurrent…

Read more

New panels for diagnosing hereditary cancer 

Apr 25, 2017

We are now providing a more targeted panel for high risk breast cancer diagnostics. The Hereditary Breast Cancer High Risk Panel analyzes seven genes associated with inherited susceptibility to breast cancer. We have also added a new 27-gene panel to our test menu for diagnosing inherited susceptibility to breast and gynecological cancer.

Read more

Blueprint receives the BioFinland Award 2017

Mar 29, 2017

We are very proud and thankful to receive the BioFinland Award 2017, today on March 29th. This is a great recognition to the whole team that constantly works to bring genetic testing of inherited disorders into mainstream healthcare, cost efficiently without ever compromising quality. The awards is presented by the Finnish Bioindustries…

Read more

Blueprint Genetics on valittu vuoden 2017 Kasvunrakentajaksi

Mar 17, 2017

Vuoden 2017 Kasvunrakentaja on Blueprint Genetics. Suomen pääomasijoitusyhdistys – FVCA:n ja PwC:n yhteistyössä järjestämän Kasvunrakentaja 2017 -kilpailun finaalissa etsittiin pääomasijoittajien yli 700 kohdeyhtiön joukosta mielenkiintoisinta ja innostavinta tarinaa. Suomen pääomasijoitusyhdistyksen ja PwC:n Kasvunrakentaja 2017 -kilpailun voittajaksi valittiin Blueprint Genetics, jonka geenitestausteknologia auttaa löytämään harvinaisia perinnöllisiä tauteja.

Read more

Comprehensive panel based approach to clinical genetics, with over 200 panels covering 14 medically relevant specialties

Feb 23, 2017

We are on a mission to challenge the standards of clinical genetic diagnostics to enable better patient care. Over the last 5 years we have developed unique sequencing technologies, in-house bioinformatics and interpretation solutions to improve rare disease genetic diagnostics. Without compromising quality and performance, our innovations are enabling more affordable…

Read more

Blueprint Genetics listed as one of the hottest start-up companies in Finland!

Feb 21, 2017

The Jury of Talouslämä, a Finnish weekly business magazine listed the top ten hottest start-up companies in Finland. The selection was made among hundreds of companies. We are delighted to be on the list for the third year in a row!   Read the whole article: http://www.talouselama.fi/lehti/talouselama-kokosi-suomen-10-kuuminta-startup-yhtiota-tassa-ne-ovat-6625765   Talouselämä 6/2017, published…

Read more

Blueprint Genetics on Kauppalehti Optio – an article about the life science and health technology innovations in Finland

Nov 24, 2016

Article about the life science and health technology innovations and the growth of the healthcare industry in Finland on Kauppalehti Optio, a Finnish business magazine. To read the whole article (available in Finnish only), click here.   Blueprint Genetics yhdessä muiden life science ja terveysalanyritysten kanssa viemässä huipputason terveysteknologiaa…

Read more

Blueprint Genetics is one of the most promising growth companies in Finland

Feb 05, 2016

Blueprint Genetics has been chosen as one of the top 20 most promising growth companies in 2016 by Talouselämä. Talouselämä, a Finnish weekly financial and business magazine, has chosen the most promising start-up companies in Finland for the fifth year in a row. The jury judged the growth and internationalization possibilities…

Read more

Blueprint Genetics becomes the first laboratory to receive ISO 15189 accreditation for a NGS pipeline from sample arrival to clinical interpretation

Feb 02, 2016

Blueprint Genetics is now an ISO 15189 standard accredited No. T292 laboratory. Accreditation is a procedure to recognize an organization’s competence to carry out specific tasks based on internationally agreed criteria. The quality management system at Blueprint Genetics complies with the international ISO 15189 standard, which specifies the quality requirements for medical…

Read more

Relevance of Truncating Titin Mutations in Dilated Cardiomyopathy

Jan 28, 2016

As a continuation to Blueprint Genetics recent collaborative studies on genetics of dilated cardiomyopathy (DCM) (Eur Heart J 2015 and PlosOne 2015), we performed meta-analysis of truncating titin variants in DCM. Others and we have previously estimated TTN truncating variants (TTNtv) – nonsense, frameshift and consensus splice site, to be responsible for…

Read more

Media kit

Subscribe to our press releases